NCT02915302 - Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children | Biotech Hunter

Enrollment

1,950

Participants

Timeline

Start Date

September 23, 2016

Primary Completion Date

March 6, 2017

Study Completion Date

March 6, 2017

Conditions

Influenza

Interventions

BIOLOGICAL

Fluzone Quadrivalent vaccine, No Preservative

0.25-mL (Pediatric Dose), Intramuscular (2016-2017 formulation)

BIOLOGICAL

Fluzone Quadrivalent vaccine, No Preservative

0.5-mL, Intramuscular (2016-2017 formulation)

Trial Locations (36)

13057

Syracuse

16505

Erie

22015

Burke

29407

Charleston

29414

Charleston

33140

Miami Beach

33142

Miami

35205

Birmingham

37388

Tullahoma

40004

Bardstown

43123

Grove City

45414

Dayton

68131

Omaha

68134

Omaha

68504

Lincoln

68505

Lincoln

68516

Lincoln

68701

Norfolk

70006

Metairie

72432

Harrisburg

76107

Fort Worth

77055

Houston

80233

Thornton

83642

Meridian

84041

Layton

84057

Orem

84067

Roy

84088

West Jordan

84095

South Jordan

84604

Provo

90241

Downey

90723

Paramount

92111

San Diego

92804

Anaheim

95815

Sacramento

97030

Gresham

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY